Replies to post #597982 on NorthWest Biotherapeutics Inc (NWBO)

[vator]

I do not really expect an answer. This what leadership should be telling analysts and their shareholders.

Great. Another scientific conference. Can anyone remember NWBO attending an investor conference over the last ten years?

[dennisdave]

I am expecting Merck to pay the same for NWBO as Gilead paid for Immunomedics so $21 billion but perhaps +$3 billion more
https://www.reuters.com/article/us-immunomedics-m-a-gilead-sciences-idUSKBN2640V8

In my view, Immunomedics can be well compared to NWBO

Just like NWBO Immunomedics was an almost zero (20 million) revenue biotech
Just like NWBO Immunomedics claimed to have a platform for solid tumors
Immunomedics catered to a much bigger market (Immunomedics Trodelvy is for breast cancer) than NWBO however with many more competitors.
Just like NWBO Immunomedics claimed Trodelvy can be used for all solid tumors
Just like NWBO Immunomedic had not started any meaningful P3 trial to provide evidence that Trodelvy is actually effective for all solid tumors

So with 1.5 billion shares O/S (1.1 now + 100 million max more dilution + 250 million for NWBO management) that would get us to around $ 16 per share buyout